Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | FABP3 | P05413 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | AKT1 | P31749 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | CDC25A | P30304 | 1/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.36 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL8910642 | 0.87 | SMN1; SMN2 (0.45) | SMN1; SMN2FABP3ADRA1ALMNAAKT1 | |
| SCHEMBL25953332 | 0.84 | BBOX1 (0.34) | SMN1; SMN2FABP3BBOX1 | |
| SCHEMBL10337116 | 0.84 | SMN1; SMN2 (0.43) | SMN1; SMN2FABP3ADRA1ALMNAAKT1 | |
| SCHEMBL25857265 | 0.83 | SMN1; SMN2 (0.46) | SMN1; SMN2FABP3ADRA1ALMNAAKT1 | |
| SCHEMBL2696626 | 0.82 | FABP3 (0.40) | SMN1; SMN2FABP3ADRA1ALMNAAKT1 | |
| SCHEMBL13619257 | 0.82 | FABP3 (0.40) | SMN1; SMN2FABP3ADRA1ALMNAAKT1 | |
| SCHEMBL18719364 | 0.81 | SMN1; SMN2 (0.47) | SMN1; SMN2FABP3ADRA1ALMNAAKT1 | |
| SCHEMBL6130069 | 0.81 | FABP3 (0.39) | SMN1; SMN2FABP3ADRA1ALMNAAKT1 | |
| SCHEMBL2694156 | 0.81 | FABP3 (0.39) | SMN1; SMN2FABP3ADRA1ALMNAAKT1 | |
| SCHEMBL6241296 | 0.81 | CA12 (0.36) | SMN1; SMN2FABP3ADRA1ALMNAAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209009-A1 | PEPTIDES COMPRISING A PHOSPHORYLCHOLINE CONJUGATE AND METHODS OF SYNTHESIZING SAME | TARSIER PHARMA LTD. (IL) | 2024-06-27 | — | — | US | disclosed |
| US-11912784-B2 | Methods of treating an eye disorder | KODIAK SCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230382983-A1 | COMPLEMENT FACTOR D ANTAGONIST ANTIBODIES AND CONJUGATES THEREOF | KODIAK SCIENCES INC. | 2023-11-30 | — | — | US | disclosed |
| US-11584790-B2 | Complement factor D antagonist antibodies and conjugates thereof | KODIAK SCIENCES INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20170190766-A1 | ANTIBODIES AND CONJUGATES THEREOF | KODIAK SCIENCES INC. | 2017-07-06 | — | — | US | disclosed |
| US-8709465-B2 | Diazeniumdiolated phosphorylcholine polymers for nitric oxide release | MEDTRONIC VASCULAR, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20110065126-A1 | SUBSTANCE-IMMOBILIZING SUBSTRATE, SUBSTANCE-IMMOBILIZED SUBTRATE, AND ANALYSIS METHOD | RIKEN (JP) | 2011-03-17 | — | — | US | disclosed |
| US-20100262238-A1 | Diazeniumdiolated Phosphorylcholine Polymers for Nitric Oxide Release | MEDTRONIC VASCULAR, INC. (US) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190766-A1 | ANTIBODIES AND CONJUGATES THEREOF | VEGFA, FLT1, HDGF | SMN1; SMN2 3694/4885FABP3 1804/4885ADRA1A 419/4885 |
| US-20230382983-A1 | COMPLEMENT FACTOR D ANTAGONIST ANTIBODIES AND CONJUGATES THEREOF | CFD, CFH, CFB | SMN1; SMN2 3074/4885FABP3 2307/4885ADRA1A 3614/4885 |
| US-20100262238-A1 | Diazeniumdiolated Phosphorylcholine Polymers for Nitric Oxide Release | NOS1, NOS3, NOS2 | SMN1; SMN2 1112/4885FABP3 2244/4885ADRA1A 3445/4885 |
| US-11912784-B2 | Methods of treating an eye disorder | VEGFA, FLT4, FLT1 | SMN1; SMN2 1353/4885FABP3 1447/4885ADRA1A 3596/4885 |
| US-20240209009-A1 | PEPTIDES COMPRISING A PHOSPHORYLCHOLINE CONJUGATE AND METHODS OF SYNTHESIZING SAME | PTMS, SRMS, SGMS1 | SMN1; SMN2 1392/4885FABP3 3462/4885ADRA1A 4359/4885 |
| US-11584790-B2 | Complement factor D antagonist antibodies and conjugates thereof | CFD, CFH, CFB | SMN1; SMN2 3074/4885FABP3 2307/4885ADRA1A 3614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.